Indena S.p.A.
http://www.indena.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Indena S.p.A.
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made
Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.
Canary Speech’s Voice AI Can Help Detect Alzheimer’s With 40-Second Conversation
AI voice tech start-up Canary Speech is developing algorithmic models for detecting behavioral health, progressive neurological and cognitive diseases based on a 40-second recording of speech. Medtech Insight caught up with Canary CEO Henry O’Connell at DHIS West to learn more about the company and its plans.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Company Information
- Industry
- Distributors
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice